Heme oxygenase (HO) induction has been demonstrated to be beneficial in limiting the extent of cellular damage after ischemia-induced acute renal failure (ARF). Because increased HO activity is associated with the production of carbon monoxide (CO) as well as the potent antioxidant bilirubin, it is unclear which of the two is of greater importance in the protective effects of HO induction. The purpose of this study was to determine the protective role of CO alone in ischemia-induced ARF. Bilateral clamping of the renal pedicle for 40 min was associated with a ninefold increase in the levels of plasma creatinine 24 h after reperfusion as compared with normal plasma creatinine levels; however, administration of CO donor compounds tricarbonyldichlororuthenium(II) dimer, ([Ru(CO) 3 Cl 2 ] 2 , 10 mg/kg) or tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO) 3 Cl(glycinate)], (CORM-3) 1 h before the onset of ischemia significantly decreased the levels of plasma creatinine 24 h after reperfusion as compared with vehicle-treated mice. Surprising, treatment with the CO donors was associated with an increase in HO activity 24 h after ischemia. For determining whether the protective effects of the CO donors were due to CO or HO-1 induction, experiments were performed in which HO was inhibited before administration of the CO donors. Pretreatment with the HO inhibitor had no effect on the level of plasma creatinine 24 h after reperfusion after treatment with the CO donor compounds. These results suggest that CO itself may be protective and limit renal damage in ischemia induced ARF. 16: 950-958, 2005.
A cute renal failure (ARF) can be caused by vascular disorders that reduce blood flow to the kidney for an extended period of time or by direct tubular injury brought on by exposure to substances that are toxic to renal tubular cells. The morbidity and mortality rates of ARF patients remain high (40 to 60%) despite some advances in the management of the disease in recent years (1) . Ischemic renal injury leads to irreversible damage after reperfusion, including necrosis and apoptosis of proximal and distal tubules. One potential mechanism for the irreversible damage is that prolonged ischemia increases the generation of reactive oxygen species (ROS), which leads to decreased levels of growth and tissue repair transcription factors and the stimulation of pro-apoptotic and inflammatory mediators in the kidney after reperfusion (2). All of these factors are believed to be involved in the progression of ARF in humans.
Heme oxygenase-1 (HO-1) catalyzes the degradation of heme in the course of which carbon monoxide (CO) is produced along with the subsequent generation of the antioxidant bilirubin. Experiments in both isolated vascular smooth muscle cells and neurons have demonstrated the ability of increased HO-1 expression to be cytoprotective against oxidative stress (3, 4) . Recent studies have also indicated a role for HO-1 overexpression in ischemia-reperfusion injury in several organs. First, in both isolated Langendorff heart preparations and the heart of transgenic mice specifically overexpressing HO-1 in cardiomyocytes, increased levels of HO-1 protein were found to protect the heart against ischemia-reperfusion injury (5, 6) . In the transgenic mice, the protective effects of HO-1 overexpression were associated with reduced inflammatory cell infiltration and decreased oxidative damage. In the liver, chemical induction as well as adenoviral delivery of HO-1 decreased hepatocyte injury after ischemia-reperfusion injury, which was also associated with decreased immune cell infiltration (7) . Neuronal overexpression of HO-1 in transgenic mice was able to decrease the infarct size in a model of middle cerebral artery occlusion (8) . Finally, in a separate study, overexpression of HO-1 in the lung was able to inhibit hypoxia-induced pulmonary hypertension and inflammation (9) .
Whether the protective effects of HO-1 induction in response to ischemia are due to production of CO or generation of bilirubin is currently unknown. Bilirubin is a potent antioxidant compound that confers cellular protection against oxidative stress (10) . Because the generation of CO gas and the formation of bilirubin by HO-1 are linked, it has been difficult to distin-guish the protective actions of each agent separately either in vitro or in vivo. One approach has been to use direct CO inhalation therapy at concentrations that increase carboxyhemoglobin levels to 25% after CO inhalation. Recent studies have indicated that CO inhalation therapy is able to protect both intestinal and renal grafts from ischemic damage in experimental models (11, 12) . However, CO inhalation therapy does have the potential to induce clinical toxicity to achieve the systemic carboxyhemoglobin levels required for therapeutic benefits. An alternative approach has been the use of transition metal carbonyls as CO-releasing molecules to distinguish the effects of CO separately from those of bilirubin generation (13, 14) . The goal of the current study was to evaluate the ability of CO to protect the kidney against ischemia-induced ARF using transition metal carbonyls as CO donors.
Materials and Methods

Reagents
Tricarbonyldichlororuthenium(II) dimer ([Ru(CO) 3 Cl 2 ] 2 ; MW ϭ 512.02 g/mol) and DMSO were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). Zn (II) Deuteroporphyrin IX 2,4 Bis ethylene glycol (ZnDPBG) was from Porphyrin Products (Frontier Scientific, Logan, UT). Stock solutions of [Ru(CO) 3 Cl 2 ] 2 were prepared in 100% DMSO and administered in vivo at a final concentration of 10 mg/kg. Solutions for in vivo administration were diluted in saline to a final concentration of 10% DMSO. Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO) 3 Cl-(glycinate)] or CORM-3; MW ϭ 295 g/mol) was synthesized from [Ru(CO) 3 Cl 2 ] 2 as described previously (13) . CORM-3 was freshly prepared in saline and administered intraperitoneally at a dose of 40 mg/kg. Stock solutions of ZnDPBG were prepared in 50 mM Na 2 CO 3 and administered at a final concentration of 42 mg/kg. Inactive CORM-3 (iCORM-3) was prepared as CORM-3 but left at room temperature for 18 h before use to allow for dissociation of the CO molecules. All solutions were freshly prepared and protected from light before administration. Hemin, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, and NADPH were obtained from SigmaAldrich Chemical Co.
Animals and Study Design
Studies were performed on 8-to 12-wk-old C57BL/6J mice (Jackson Labs, Bar Harbor, ME) that were fed a standard laboratory diet. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center. Mice were anesthetized with sodium pentobarbital (50 mg/kg) and placed on a heating pad. For intravenous infusions, drug or vehicle was infused via the jugular vein in a volume of 0.2 ml. After administration of the drug or vehicle, the catheter was removed, the vein was tied off, and the incision was sutured. Renal ischemia was induced by clamping both renal pedicles for 40 min with vascular microclamps. After clamp removal, the muscle and skin were sutured separately and the mice were allowed recovery on heated pads.
In the first set of experiments, [Ru(CO) 3 Cl 2 ] 2 or vehicle was administered via intravenous infusion 1 h before the onset of ischemia. Mice then were killed 24 or 72 h after reperfusion by CO 2 narcosis. In the second set of experiments, [Ru(CO) 3 Cl 2 ] 2 or vehicle was administered 1 h after reperfusion. Mice then were killed 24 h after reperfusion. In the last set of experiments, mice were given ZnDPBG or vehicle by intraperitoneal injection 1 h before administration of [Ru(CO) 3 Cl 2 ] 2 or vehicle. Mice then were exposed to renal ischemia as above and killed 24 h after reperfusion.
Two injections of CORM-3 (40 mg/kg) or iCORM (0.2 ml) were administered 18 h and 1 h before the onset of renal ischemia as described previously (13) . In a separate set of experiments, ZnDPBG was administered 1 h before the second CORM-3 dose and the mice then were subjected to renal ischemia. All mice in these protocols were killed 24 h after reperfusion.
Measurement of Plasma Creatinine
Blood was collected at the time when the mice were killed by cardiac puncture (400 l of whole blood). Plasma creatinine was determined by the Jaffe method using a commercially available kit (Sigma). Plasma creatinine values are expressed as mg/dl.
Collection of Urine
Urine was collected from mice that were housed individually in custom-designed metabolic cages. Mice were placed in the metabolic cages 3 d before the onset of renal ischemia. Twenty-four-hour urine samples were collected over the first 48 h for controls. Mice were removed from the metabolic cages to undergo surgery and then immediately returned to the cages after regaining consciousness. The mice then were housed in the metabolic cages until they were killed.
HO Assay
HO assay was performed on kidney microsomes as described previously (15) . Kidneys were homogenized in 250 mM sucrose, 10 mM KPO 4 , 1 mM EDTA, and 0.1 mM PMSF (pH 7.7) in the presence of protease inhibitors (2 g/ml aprotinin, leupeptin, and pepstatin). The homogenate then was centrifuged at 3000 ϫ g for 15 min at 4°C, and the supernatant collected and further centrifuged at 10,000 ϫ g for 15 min at 4°C followed by 100,000 ϫ g for 60 min at 4°C. The microsomal pellet then was resuspended by brief sonication in 100 mM KPO 4 , 1 mM EDTA, 1 mM dithiothreitol, and 30% glycerol (pH 7.25). The protein concentration was measured using a Bio-Rad (Hercules, CA) protein assay with BSA standards. The reaction was carried out in a 1.2-ml reaction that contained mouse liver cytosol (1 mg), 2 mM glucose-6-phosphate, 0.2 units of glucose-6-phosphate dehydrogenase, 0.8 mM NADPH, 20 M hemin, and 0.5 mg of microsomal protein. The reactions were incubated for 1 h at 37°C in the dark. The formed bilirubin was extracted with chloroform, and the change in optical density (⌬OD) at 464 to 530 nm was measured using an extinction coefficient of 40 mM/cm for bilirubin. HO activity was expressed as picomoles of bilirubin formed per hour per milligram of microsomal protein.
Measurement of Carboxyhemoglobin levels
Carboxyhemoglobin (COHb) levels were measured using the modified method of Rodkey et al. (16, 17) . In summary, 40 l of whole blood was collected from the retro-orbital vein of an anesthetized mouse at several different time points after administration of CORM-3 (40 mg/ml). Twentyfive microliters of the sample was hemolyzed in 3 ml of 0.01 mol/L KH 2 PO 4 /K 2 HPO 4 buffer. One hundred microliters of this lysate was mixed with 1.15 ml of diluting solution (0.1 mol/L KH 2 PO 4 /K 2 HPO 4 buffer [pH 6 .85] that contained 1.25 mg/ml sodium hydrosulfite), and the absorbance of this mixture was read at 420 and 432 nm. Percentage COHb was calculated as follows:
where AR is the ratio A 420 /A 432 ; F 1 , F 2 , and F 3 were calculated from published molar absorptivities of mouse hemoglobin,
Western Blot and Immunohistochemistry
Western Blots for HO-1 protein were performed on microsomes prepared from whole kidneys as described above. Samples of 10 g of microsomal protein were boiled in Laemmli sample buffer (Bio-Rad) for 5 min and electrophoresed on 7.5% SDS-polyacrylamide gels and blotted onto nitrocellulose membrane. Membranes were blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE) for 2 h at room temperature, then incubated with rabbit anti-HO-1 polyclonal antibody (StressGen, Vancouver, BC, Canada; 1:2000) as well as a mouse anti-␤-actin antibody (Gentest; 1:5000) overnight at 4°C. The membranes then were incubated with Alex 680 goat anti-rabbit IgG (Molecular Probes, Eugene, OR) and IRDye 800 goat anti-mouse IgG (Rockland, Gilbertsville, PA) for 1 h at room temperature. The membranes then were visualized using an Odyssey infrared imager (Li-COR), which allows for the simultaneous detection of two proteins. Densitometry analysis was performed using Odyssey software (LI-COR). Levels of HO-1 protein are expressed as the ratio of HO-1 to ␤-actin for each sample.
Western blots for urinary neutrophil gelatinase-associated lipocalin (NGAL) were performed on 25 g of urinary protein (approximately 3 l) in which the total protein levels were determined using a Bio-Rad protein assay as above. Urine samples were run in duplicate on 12% SDS-polyacrylamide gels with one gel that was stained for total protein using Coomassie blue staining and the other gel transferred to a nitrocellulose membrane as above. The membrane then was blocked as above and then incubated with an NGAL monoclonal antibody (AntibodyShop, Gentofte, Denmark; 1:500) overnight at 4°C. The membranes then were incubated with an Alex 680 goat anti-mouse IgG (Molecular Probes) for 1 h at room temperature. Membranes then were visualized using an Odyssey infrared imager as above.
Immunohistochemistry was performed on formalin-fixed tissue samples using the same rabbit anti-HO-1 polyclonal antibody as above. Antibody labeling was visualized using fluorescence-labeled secondary antibodies. All samples were examined using fluorescence confocal microscopy (Lica Microsystems, Exton, PA).
Histologic Analysis
Kidneys were removed from mice immediately after they were killed, cut in half, fixed in neutral-buffered formalin, and embedded in paraffin. Sections (5 m thick) of formalin-fixed, paraffin-embedded tissue were mounted on glass slides and stained with hematoxylineosin for general histology and quantitative analysis. All tissues were evaluated without investigator knowledge of the group from which it originated.
Tubular injury area was quantified using images of cortex and outer medulla (ϫ10 magnification) captured with a Nikon Coolpix digital camera (Nikon Corp., Melville, NY). Images were analyzed using the point-counting method. Grids that contained 70 points were placed over the images, and points that were in contact with injured tubules were counted and divided by total number of points on the grid.
Statistical Analyses
Mean Ϯ SEM are presented. The significant difference in mean values was evaluated by either a t test or by Dunnett paired t test for multiple comparisons. P Ͻ 0.05 was considered to be statistically significant.
Results
Pretreatment with [Ru(CO) 3 Cl 2 ] 2 or CORM-3 Lowers Plasma Creatinine 24 H after Ischemia
Bilateral clamping of the renal pedicle for 40 min was associated with a ninefold increase in the levels of plasma creatinine 24 h after reperfusion as compared with normal plasma creatinine levels ( Figure 1A) . However, administration of [Ru(CO) 3 Cl 2 ] 2 or CORM-3 before the onset of ischemia significantly decreased the levels of plasma creatinine 24 h after reperfusion as compared with vehicle-treated mice ( Figure 1A) . The protective effect of [Ru(CO) 3 Cl 2 ] 2 administration seemed to be limited to 24 h after reperfusion as there was no significant difference in the levels of plasma creatinine between [Ru(CO) 3 Cl 2 ] 2 -and vehicle-treated mice 72 h after ischemia ( Figure 1B) . However, there was a 25% mortality rate (two of eight) observed in vehicle-treated mice in the 72-h period, and no mortality was observed in the [Ru(CO) 3 Cl 2 ] 2 -treated group.
Next, we wanted to determine whether administration of [Ru(CO) 3 Cl 2 ] 2 after ischemia would be able to prevent the Figure 1 . (A) Plasma creatinine levels 24 h after 40 min of bilateral renal ischemia when CO donor compounds were administered before ischemia. Control group is the value obtained from normal mouse plasma. *Statistically different (P Ͻ 0.05) from corresponding value in ischemiaϩvehicle group. (B) Plasma creatinine levels 72 h after 40 min of bilateral renal ischemia when tricarbonyldichlororuthenium(II) dimer ([Ru(CO) 3 Cl 2 ] 2 ) was administered before ischemia. increase in plasma creatinine similar to that of treatment before ischemia. Mice were infused with [Ru(CO) 3 Cl 2 ] 2 (20 mol/kg) 1 h after reperfusion after 40 min of bilateral renal ischemia. Postadministration of [Ru(CO) 3 Cl 2 ] 2 was not able to blunt the increase in plasma creatinine 24 h after reperfusion as compared with vehicle treatment (Figure 2) .
Administration of CO Donors Induces Renal HO-1 Levels 24 H after Ischemia
We evaluated the levels of HO-1 protein in the kidneys of nonischemic-, ischemic-, [Ru(CO) 3 Cl 2 ] 2 -, vehicle-, CORM-3-, and iCORM-3-treated mice at 24 h after ischemia. The levels of HO-1 protein were higher in mice that were treated with both CO donors as compared with control ischemic mice (Figure 3) .
Inhibition of Renal HO-1 Activity Does Not Prevent the Lowering of Plasma Creatinine 24 Hours after Ischemia by Previous Administration of CO Donors
Because administration of each of the CO donor compounds increases the levels of HO-1 in the kidney, we wanted to determine whether the protective effects observed were due to increases in CO or HO-1 induction. To test this possibility, we performed experiments in which mice were pretreated with the specific HO-1 inhibitor ZnDPBG 1 h before administration of the CO donor compounds to inhibit endogenous HO-1 in the kidney. Inhibition of renal HO-1 activity with ZnDPBG did not impair the ability of [Ru(CO) 3 Cl 2 ] 2 or CORM-3 to lower plasma creatinine 24 h after ischemia (Figure 4) . Treatment of mice with ZnDPBG tended to increase the levels of plasma creatinine 24 h after ischemia as compared with untreated mice; however, this difference did not achieve statistical significance. HO activity then was measured in kidneys from each treatment group at 24 h after ischemia. ZnDPBG was able to block completely the increase in renal HO activity 24 h after ischemia in CORM-3-treated mice and led to a significant reduction of HO activity in [Ru(CO) 3 Cl 2 ] 2 -treated mice ( Figure 5 ).
Pretreatment with CO Donors Reduces the Level of Renal Tubule Cell Damage 24 H after Ischemia
To determine whether pretreatment with CO donors could reduce renal tubular damage, we performed histologic analysis on kidneys from mice 24 h after 40 min of bilateral renal ischemia. Renal ischemia was associated with significant tubular injury in both the juxtamedullary cortex and the outer medulla in control and vehicle-treated mice. The tubular injury included sloughing of tubular cells, cast formation, and karyolysis. The S3 segment of the proximal tubules seemed to be most affected; however, once ischemic injury has commenced, it can be difficult to distinguish between proximal and distal tubules ( Figure 6A ). Total tubule injury as well as outer medullary injury was significantly decreased in the CORM-3-treated mice and was lower in the CORM-3ϩZnDPBG-treated mice, although it did not reach statistical significance. Juxtamedullary injury was significantly decreased in both CORM-3-and CORM-3ϩZnDPBG-treated mice ( Figure 6B ). The levels of HO-1 protein were increased in both the cortex and the outer medulla after ischemia. Significant induction of HO-1 in the cortex was observed after treatment with CORM-3, iCORM-3, and CORM-3ϩZnDPBG; however, these drugs had less of an effect on HO-1 induction in the outer medulla ( Figure 7) .
Recent studies have identified NGAL as a sensitive urinary marker for renal tubular damage in ischemic ARF (18) . We evaluated the urinary levels of NGAL in each group of mice 24 h after ischemia. A considerable increase in urinary NGAL levels was observed 24 h after ischemia in control and iCORMtreated mice (Figure 8 ). Minimal increase in urinary NGAL was observed in CORM-3-and CORM-3ϩZnDPBG-treated mice 24 h after ischemia (Figure 8 ), indicating less renal tubule cell damage in these groups.
Effects of CORM-3 on COHb Levels
We evaluated COHb levels in the blood at varying times after treatment with CORM-3 (40 mg/kg). No significant changes in %COHb levels were observed up to 360 min after CORM-3 administration (Table 1) .
Discussion
The induction of HO-1 in the kidney after ischemia is thought to be a critical part of the protective mechanisms of the renal tubules to guard against ischemia-induced injury. HO-1 is essential for the breakdown of heme that accumulates from several intracellular sources after ischemia. The breakdown of heme by HO-1 leads to the production of the potent antioxidant bilirubin as well as the formation of Fe 3ϩ and CO gas. Several studies have demonstrated the protective effects of increased HO-1 activity in the kidney after ischemia (19, 20) ; however, the precise mechanism by which increased HO-1 activity affords protection after ischemia has yet to be proved definitively. Because increased HO-1 activity is associated with an increase in bilirubin as well as CO production, it has not been possible to dissect out the contributions of each to the protective actions of HO-1 induction in the kidney after ischemia.
Recent studies have identified transition metal carbonyl compounds as tools that can specifically act as CO donors (21) . The water-soluble form of these compounds, CORM-3, has been used to limit the extent to ischemic damage to the heart in both in vitro and in vivo models of cardiac ischemia-reperfusion injury (13, 22) . No difference in protection was reported when the CORM-3 compound was given before or just before the end of the ischemic period in the in vivo model, and these protective effects were observed in the absence of any measurable changes in COHb levels in the blood (22) . However, the ability of CORM-3 administered after reperfusion to decrease infarct size was not determined. Results from the current study demonstrate that the transition metal carbonyl compounds are effective in preventing the increase in plasma creatinine after a 40-min bout of ischemia if the compounds are administered before the ischemic episode. Our results agree with those of Guo et al. (22) in that we observed the protective effects of the CO donors in the absence of any increases in COHb levels. This observation suggests that these compounds are sufficiently concentrated in the kidney to increases local levels of CO in the absence of any decreases in COHb levels. This aspect of these compounds makes them attractive alternatives to CO inhalation therapy, which requires high levels of COHb in the blood to be achieved to be effective (12) . We also found that these compounds seem to lose their beneficial qualities when administered after the ischemic episode. This property may make these compounds useful in a transplantation setting, where they could be administered before transplantation to improve the function and survival of the kidney graft.
There have been several reports that inhalation of CO can be protective against acute rejection of intestine, lung, and kidney transplants (11, 12, 23, 24) . The protective actions of CO inhalation in transplantation are associated with a decrease in inflammation and apoptosis. Studies in the lung indicate that CO can act through the p38 mitogen-activated protein kinase pathway Figure 4 . Effect of Zn (II) Deuteroporphyrin IX 2,4 Bis ethylene glycol (ZnDPBG) on plasma creatinine levels 24 h after 40 min of bilateral renal ischemia when CO donor compounds were administered before ischemia. ZnDPBG was given 1 h before administration of the CO donor compounds. *Statistically different from corresponding value in vehicleϩvehicle-treated mice. Figure 5 . Kidney HO activity 24 h after ischemia. ZnDPBG was administered 1 h before CO donors. CO donors were given before the onset of 40 min of bilateral renal ischemia. *Statistically different (P Ͻ 0.05) from corresponding value in control ischemic kidneys.
Statistically different (P Ͻ 0.05) from corresponding value in [Ru(CO) 3 Cl 2 ] 2 -treated mice.
to decrease apoptosis by inhibition of Fas/Fas ligand as well as by stimulation of antiapoptotic proteins such as Bcl-2 (25, 26) . The anti-inflammatory actions of CO inhalation are associated with a decrease in cytokines such as IL-6 and inducible nitric oxide synthase as well as an increase in the total antioxidant power (11) . Because analogous mechanisms are believed to contribute to tissue injury after renal ischemia, it is possible that the CO released from transition metal carbonyls is able to Figure 6 . Hematoxylin-eosin-stained sections of the juxtamedullary cortex in control ischemic-(A), vehicle-(B), CORM-3-(C), and CORM-3ϩZnDPBG-treated (D) mice 24 h after 40 min of bilateral renal ischemia. All drugs were administered before the onset of renal ischemia. (B) Tubular injury in each group as determined by using the point-counting method. Grids that contained 70 points were placed over the images, and points that were in contact with injured tubules were counted and divided by total number of points on the grid (n ϭ 6 for each group). *Statistically different (P Ͻ 0.05) from corresponding value in control ischemic kidneys.
activate similar pathways to protect the kidney against ischemia-reperfusion injury. These pathways were not examined in the current study but are important areas in which future studies can be focused. That transition metal carbonyls did not offer any protection when administered after the ischemic episode suggests that upregulation of these pathways before ischemic injury is critical to offer protection against renal ischemiareperfusion injury.
A surprising finding of the current study was the ability of the CO-releasing compounds to induce the levels of HO-1 protein in the kidney. This effect on HO-1 protein levels was also observed with the inactive form of the water-soluble CO donor iCORM-3, which is also derived from the [Ru(CO) 3 Cl 2 ] 2 compound. Although iCORM-3 was able to increase the levels of HO-1, it did not offer significant protection against ischemiainduced ARF in the present study. This was surprising given the number of previous studies that have demonstrated the protective effects of previous induction of HO-1 to limit renal damage after ischemia (19, 20) . The reason for this observation is unknown, but it is possible that because we did not detect a significant increase in HO activity by iCORM-3, the HO-1 induction failed to reach a significant threshold to afford protection against ischemia-induced ARF in the present study.
The regulation of HO-1 gene expression by hypoxia has been an area of intensive research. Hypoxia in rat, mouse, and bovine cells increases HO-1 levels as a result of the stabilization of hypoxia inducible factor-1 (HIF-1) by inhibition of prolyl-hydroxylation of the HIF-1␣ subunit by HIF prolyl-hydroxylase 2 (27) . However, hypoxia-mediated repression of HO-1 expression has been observed in human-derived cell lines. The repression of HO-1 by hypoxia in these cells is mediated by induction of the HO-1 repressor Bach1, which is able to bind to a Maf recognition element in the promoter of the human HO-1 gene (28). Bach1-mediated repression of HO-1 may have significant clinical significance given that recent studies have reported lower HO-1 levels in cadaveric donor kidneys (29) .
The increase in HO-1 by metals seems to be mediated through the regulation of the transcription factors Nrf2 and Bach1. In response to increased levels of CdCl 2 , the half-life of Nrf2 protein is increased through a mechanism involving the activation of p38 (30) . Recent studies have also indicated that nuclear export of the HO-1 repressor Bach1 is an important component of the increased expression of HO-1 by heavy metals such as cadmium (31) . Whether any of these pathways of HO-1 gene regulation are affected by [Ru(CO) 3 Cl 2 ] 2 treatment was not examined in the current study but is clearly an area that requires further investigation.
Although administration of the transition metal carbonyl compounds was associated with the induction of HO-1, these compounds still were able to protect the kidney from ischemic damage even after HO activity was inhibited with ZnDPBG. The dose of ZnDPBG used in this study was able to block completely the increase in HO activity associated with use of the transition metal carbonyl compounds 24 h after ischemic injury. We were able to document specific inhibition of the CO donor-stimulated increase in HO activity 24 h after ischemic injury; however, it is possible that HO activity still could be Figure 8 . Western blot of urinary neutrophil gelatinase-associated lipocalin levels 24 h after ischemia. Lanes 1 and 2, control mice before renal ischemia; lanes 3 to 5, control mice after ischemia; lanes 6 and 7, iCORM-3-treated mice; lanes 8 and 9, CORM-3-treated mice; lanes 10 and 11, CORM-3ϩZnDPBG-treated mice. Figure 7 . Immunohistochemical localization of HO-1 in the cortex and the outer medulla. Tissues from ischemic mice were collected 24 h after ischemia, and all compounds were administered before ischemia.
increased at earlier time points after reperfusion and that this influences the protective actions of the CO donors used in the present study. This possibility merits further investigation. Also, although metalloporphyrins such as ZnDPBG are potent inhibitors of HO-1, they can have effects on other heme-containing proteins, such as nitric oxide and soluble guanylate cyclase (32) . Nonetheless, our data support the conclusion that increases in CO alone are sufficient to protect the kidney from ischemia-induced ARF.
Another potential mechanism of the protective effects of CO pretreatment in ischemia-induced ARF may be the ability of CO to preserve GFR as well as intrarenal blood flow after ischemia. Several studies have reported a sustained decrease in GFR and renal blood flow after ischemia/reperfusion injury (33) . The decrease in GFR after renal ischemia/reperfusion is associated with an increased production of endothelin and reactive oxygen species, which may be responsible for increasing renal vascular resistance after ischemia/reperfusion (34, 35) . One of the most sensitive regions of the kidney to alterations in blood flow after ischemia is the medullary circulation (36, 37) . Recent studies have demonstrated that CO is endogenously produced in this region of the kidney and that this locally produced CO plays an important role in the regulation of medullary blood flow (38) . Thus, it is possible that previous administration of the CO donors is able to preserve medullary blood flow, thus limiting the extent of damage to this area of the kidney after ischemia.
It is clear that the role of CO in protecting the kidney from ischemic injury is an area that warrants further investigation. CO donor compounds afford us an opportunity to examine the mechanism by which this gas can protect the kidney from ischemic injury. These results suggest that generation of CO gas may be a critical component of the protective actions of HO-1 induction after ischemia and may be important to protect the kidney in other pathologic conditions in which HO-1 is induced in the kidney. 
